Biotech Values

[mcbio]

Re: Debiopharm/IDIX

Although NVS’ financial commitment in this deal may be small, the deal does show that NVS remains interested in HCV in spite of the likelihood that Albuferon will be a commercial flop. This makes it somewhat puzzling that NVS opted not to license IDIX’s IDX184 last year.

Perhaps there was an offer from NVS that IDIX deemed too low? I assume that IDIX has a right to reject any offer from NVS that it deems unsatisfactory.